Prevalence of Gastroesophageal Reflux Disease in Primary Care Patients With Upper Gastrointestinal Symptoms

Completed

• Conditions: Gastroesophageal Reflux Disease

• Registration Number: NCT01020890
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to provide data on the gastroesophageal reflux disease (GERD) prevalence as percentage of patients with upper gastrointestinal (GI) symptoms that are identified with GERD using the Gerd-Q Questionnaire.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-11
• Study First Submitted: 2009-11-25
• Study First Submitted QC: 2009-11-25
• Study First Posted: 2009-11-26
• Primary Completion: 2010-04
• Study Completion: 2010-04
• Status Verified: 2010-07
• Last Update Submitted: 2010-07-09
• Last Update Posted: 2010-07-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2210

Inclusion Criteria

• Patients with upper gastrointestinal symptoms

Exclusion Criteria

• History of oesophageal, gastric or duodenal surgery
• Current treatment with antiinflammatory drugs, including OTC
• Current treatment with proton pump inhibitors ang H2-blockers

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Research Site; 🇧🇬 Yambol, Bulgaria